189119-39-9Relevant academic research and scientific papers
Convergent synthesis of two 14C-labeled β3- adrenergic receptor agonists
Czeskis, Boris A.,Wheeler, William J.,Clodfelter, Dean K.
, p. 663 - 673 (2007/10/03)
The synthesis of β3-adrenergic receptor agonists A and B with radiolabeled amide fragment, required for drug disposition studies, was accomplished based on initial formation of 2-(4-(2-amino-2-methylpropyl)phenoxy) -5-[14C]-cyanopyri
Carbazolyl-substituted ethanolamines as selective beta -3 agonists
-
, (2008/06/13)
PCT No. PCT/US97/15230 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Aug. 28, 1997 PCT Pub. No. WO98/09625 PCT Pub. Date Mar. 12, 1998Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.
SELECTIVE BETA3 ADRENERGIC AGONISTS
-
, (2015/09/24)
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β 3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I:
Selective beta3 adrenergic agonists
-
, (2008/06/13)
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and
